Table 1.
Cell viability assay on seven osteosarcoma cell lines treated with pazopanib, trametinib, and their constant combination. Concentrations inhibiting 50% of the cell growth (IC50) values with 95% confidence intervals after 72 h of treatment with scalar doses of pazopanib (20, 10, 5, 2.5, and 1.25 µM), trametinib (50, 20, 10, 5, and 2.5 nM), and their constant combination. Drug synergism is expressed as a combination index (CI), calculated at IC50; Est. SD = estimated standard deviation.
| Cell Line | IC50 Pazopanib (95% CI) µM | IC50 Trametinib (95% CI) nM | Combination Index ± Est. SD | ||
|---|---|---|---|---|---|
| Single Agent | Combination | Single Agent | Combination | ||
| HOS | 14.26 (12.43–16.35) | 8.99 (8.88–9.10) | >50 | 22 (22–23) | 0.74 ± 0.09 |
| KHOS/NP | 16.98 (14.21–20.32) | 0.88 (0.42–1.84) | 4 (2–6) | 2 (1–5) | 0.57 ± 0.34 |
| MG63 | 9.84 (8.64–11.20) | 3.36 (2.92–3.86) | 45 (28–62) | 8 (7–10) | 0.53 ± 0.06 |
| MNNG-HOS | 10.96 (9.39–12.8) | 3.23 (2.25–4.62) | 25 (22–28) | 8 (6–11) | 0.62 ± 0.12 |
| SAOS-2 | >20 | 2.77 (2.20–3.48) | 24 (7–74) | 7 (5–9) | 0.32 ± 0.04 |
| SJSA-1 | 6.00 (5.45–6.6) | 4.53 (4.14–4.96) | 18 (15–21) | 11 (10–12) | 0.99 ± 0.06 |
| U-2OS | 10.32 (9.34–11.41) | 4.57 (4.25–4.91) | >50 | 11 (11–12) | 0.56 ± 0.04 |